Brief: Humacyte Announces FDA Approval Of Symvess For The Treatment Of Extremity Vascular Trauma
20/12/2024 03:51
Dec 19 (Reuters) - Humacyte Inc HUMA.O :
* HUMACYTE ANNOUNCES FDA APPROVAL OF SYMVESS™ (ACELLULAR
TISSUE
ENGINEERED VESSEL-TYOD) FOR THE TREATMENT OF EXTREMITY VASCULAR
TRAUMA
Source text: ID:nGNX4lCXD6
Further company coverage: HUMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Humacyte
See all newsBrief: Humacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Humacyte falls after wider-than-expected quarterly loss
Humacyte Inc reports results for the quarter ended June 30 - Earnings Summary